Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Evaluation of outcomes from transscleral cyclodiode laser, in a tertiary referral centre, including the outcomes in neovascular glaucoma in the era of anti-VEGF

Poster Details

First Author: S. whitlow IRELAND

Co Author(s):    N. Collins   A. Doyle                 

Abstract Details

Purpose:

To assess the outcomes from transscleral cyclodiode laser, in a tertiary referral centre, including the outcomes in neovascular glaucoma in the era of anti-VEGF

Setting:

Retrospective chart review of patients who underwent cyclodiode laser between May 2014 and Sept 2015 in a tertiary centre. 106 patients had undergone cyclodiode laser.

Methods:

59 patients (60 eyes) had sufficient follow-up data in the study. Data included: demographics including age, gender, type of glaucoma, prior glaucoma surgery or cyclodiode treatment and for neovascular glaucoma (NVG) whether the patient had prior treatment with PRP or anti-VEGF injection; cyclodiode laser parameters including total energy administered, concomitant anti-VEGF treatment and whether the patient was under the care of a glaucoma subspecialist (GC) or a consultant not specializing in glaucoma (NGC). Data was collected on the following variables for patients pre- and post-cyclodiode laser: intraocular pressure (IOP), best corrected visual acuity (BCVA) and number of glaucoma medications.

Results:

There was a significant reduction in mean IOP from 34.2mmHg (StDev 11.7mmHg) to 20.9mmHg (StDev 10.2mmHg) at 6 weeks post cyclodiode laser treatment (student paired t-test (2-tailed) p < 0.0001). 65% of patients achieved an IOP < 22mmHg or decreased IOP by at least 30%. 35% of patients were able to decrease the number of IOP lowering agents. 8 patients had undergone prior PRP or anti-VEGF treatment for NVG, and 5 patients had no prior treatment. Patients treated with prior PRP / anti-VEGF had lower pre- and post-cyclodiode IOP (mean IOP 33.9 and 18.5 respectively) than those without prior treatment (mean IOP 43.2 and 21.8mmHd respectively) although the differences were not statistically significant

Conclusions:

Cyclodiode laser is an effective way to decrease IOP and to decrease the number of IOP medications. This study did not show the any significant difference in the whether a Glaucoma or non glaucoma specialist preformed the procedure. This study suggests that patients who had NVG that were previously treated with prior PRP/Avastin had greater IOP decrease with cyclodiode laser than patients without prior PRP/Avastin. However a larger study would be required to have the result statistically significant.

Financial Disclosure:

NONE

Back to Poster listing